Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.2337/db13-0399

http://scihub22266oqcxt.onion/10.2337/db13-0399
suck pdf from google scholar
23835338!3806621!23835338
unlimited free pdf from europmc23835338    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid23835338      Diabetes 2013 ; 62 (11): 3817-27
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Cyclodextrin protects podocytes in diabetic kidney disease #MMPMID23835338
  • Merscher-Gomez S; Guzman J; Pedigo CE; Lehto M; Aguillon-Prada R; Mendez A; Lassenius MI; Forsblom C; Yoo T; Villarreal R; Maiguel D; Johnson K; Goldberg R; Nair V; Randolph A; Kretzler M; Nelson RG; Burke GW 3rd; Groop PH; Fornoni A
  • Diabetes 2013[Nov]; 62 (11): 3817-27 PMID23835338show ga
  • Diabetic kidney disease (DKD) remains the most common cause of end-stage kidney disease despite multifactorial intervention. We demonstrated that increased cholesterol in association with downregulation of ATP-binding cassette transporter ABCA1 occurs in normal human podocytes exposed to the sera of patients with type 1 diabetes and albuminuria (DKD(+)) when compared with diabetic patients with normoalbuminuria (DKD(-)) and similar duration of diabetes and lipid profile. Glomerular downregulation of ABCA1 was confirmed in biopsies from patients with early DKD (n = 70) when compared with normal living donors (n = 32). Induction of cholesterol efflux with cyclodextrin (CD) but not inhibition of cholesterol synthesis with simvastatin prevented podocyte injury observed in vitro after exposure to patient sera. Subcutaneous administration of CD to diabetic BTBR (black and tan, brachiuric) ob/ob mice was safe and reduced albuminuria, mesangial expansion, kidney weight, and cortical cholesterol content. This was followed by an improvement of fasting insulin, blood glucose, body weight, and glucose tolerance in vivo and improved glucose-stimulated insulin release in human islets in vitro. Our data suggest that impaired reverse cholesterol transport characterizes clinical and experimental DKD and negatively influences podocyte function. Treatment with CD is safe and effective in preserving podocyte function in vitro and in vivo and may improve the metabolic control of diabetes.
  • |ATP Binding Cassette Transporter 1/*biosynthesis[MESH]
  • |Adult[MESH]
  • |Albuminuria/physiopathology[MESH]
  • |Animals[MESH]
  • |Cells, Cultured[MESH]
  • |Cholesterol/metabolism[MESH]
  • |Cyclodextrins/pharmacology/*therapeutic use[MESH]
  • |Diabetes Mellitus, Type 1/blood/physiopathology[MESH]
  • |Diabetic Nephropathies/blood/*physiopathology[MESH]
  • |Down-Regulation[MESH]
  • |Humans[MESH]
  • |Islets of Langerhans/drug effects[MESH]
  • |Kidney Glomerulus/physiopathology[MESH]
  • |Male[MESH]
  • |Mice[MESH]
  • |Mice, Obese[MESH]
  • |Middle Aged[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box